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Clinical Summary:  
• Distal renal tubular acidosis, which can be caused by a variety of congenital or acquired 
conditions, predisposes to calcium phosphate stones via pathophysiologic intermediates of 
alkalinuria, hypocitraturia, and to a lesser extent hypercalciuria. 
• Incomplete distal renal tubular acidosis usually escapes routine clinical detection and 
its diagnosis requires the demonstration of inadequate urinary acidification from provocative 
acid loading testing but such traits are not “normal vs. abnormal” but in fact is a continuum, 
and at the present momentum it is unclear whether these tests should extend from the human 
research lab into clinical practice.  
• The mainstream therapy of complete and incomplete dRTA is still alkali supplement 
such as potassium citrate, to render the urine less lithogenic by raising citrate and to prevent 
bone loss, but the citraturic effect can be offset by worsening alkalinuria so cautious dose 
titration is of critical importance.  
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ABSTRACT 
Renal tubular acidosis is comprised of a diverse group of congenital or acquired disease with 
the common dominator of defective renal acid excretion with protean manifestation but in 
adults, recurrent kidney stones and nephrocalcinosis are main modes of presentation. Calcium 
phosphate stones and nephrocalcinosis are frequently encountered in distal hypokalemic RTA 
type 1. Alkaline urinary pH, hypocitraturia, and less frequently hypercalciuria, are the tripartite 
lithogenic factors in dRTA predisposing to calcium phosphate stone formation; the latter two 
are also commonly encountered in other causes of urolithiasis. While the full blown syndrome 
is easily diagnosed by conventional clinical criteria, an attenuated forme fruste called 
incomplete dRTA typically evades clinical testing and only uncovered by provocative acid 
loading challenges. Stone formers that cannot acidify urine pH <5.3 during acid loading are 
considered to have incomplete dRTA. However, urinary acidification capacity is not a 
dichotomous but rather a continuous trait so incomplete dRTA is not a distinct entity but maybe 
one end of a spectrum. Recent findings suggest that incomplete dRTA can be attributed to 
heterozygous carriers of hypofunctional V-ATPase. The value of incomplete dRTA diagnosis 
by provocative testing and genotyping candidate genes are valuable research tools but 
remains unclear at the moment whether they alter clinical practice, and need further 
clarification. No randomized control trials have been performed in SF with dRTA or calcium 
phosphate stones and until such data is available, treatment of calcium phosphate stones are 
centered on reversing the biochemical abnormalities encountered in the metabolic work-up. 
SF with type I dRTA should receive alkali therapy, preferentially in the form of K-citrate 
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Introduction 
Homeostasis or fixité du milieu intérieur, as first described by the pioneering French 
physiologist Claude Bernard, is a prerequisite for multicellular life and ensured by multiple 
organs, including the kidney. In addition to numerous other homeostatic tasks, the kidney plays 
a pivotal role in maintaining body acid-base balance and body fluid pH by the reclamation of 
bicarbonate from the glomerular filtrate and excretion of net acid. Renal net acid excretion 
regenerates bicarbonate decomposed by non-volatile acids. If renal excretion is defective or 
overwhelmed as in the case of non-volatile acid overproduction, metabolic acidosis ensues. In 
contrast, renal tubular acidosis (RTA) is a group of congenital or acquired disorders 
characterized not by non-volatile acid overproduction, but defective renal acid excretion in the 
setting of preserved glomerular filtration rate (GFR). Traditionally, RTA is classified as 
“proximal” or “distal”, depending on the site of the tubular lesion. There is also a popular but 
less informative numeric classification separating RTA to types I –IV (see Table 1). Clinically, 
all forms of RTAs – with the exception of the incomplete form of distal RTA- present as normal 
anion gap metabolic acidosis. To secure the diagnosis of RTA, other forms of normal anion 
gap acidosis need to be excluded; which includes non-renal alkali-losing states and 
overproduction acidosis with successful renal excretion of the conjugate anion of the acid. 
Depending on the type of RTA, serum K and urinary pH are either high or low and allow further 
separation (see Table 1)1. Low urine ammonium and its surrogate of highly positive urinary 
anion gap, are present in distal RTAs (dRTAs) but typically not in in proximal RTA (pRTA).  
The clinical presentation of RTA ranges from completely asymptomatic to increasingly dire 
outcomes such as recurrent kidney stones, nephrocalcinosis, end stage renal disease, and 
sudden death from hypokalemic dysrhythmias. The main focus of this review lies on kidney 
stone formation in incomplete dRTA (idRTA), but we provide a briefly account of the 
association of all RTA forms with renal stone disease. 
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Proximal RTA (Type II) 
Impaired tubular bicarbonate reclamation, either isolated or generalized in the form of a 
Fanconi syndrome, is the hallmark of pRTA 2. Isolated forms of pRTA are mostly congenital 
with either autosomal-recessive or autosomal-dominant inheritance. While the former is due 
to bi-allelic mutations in the basolateral sodium/bicarbonate cotransporter NBCe1, encoded by 
the SLC4A4 gene, the cause of the latter remains elusive 2, 3. Although patients with pRTA are 
acidemic (low blood pH), daily accruing non-volatile acid equivalents can be eliminated by the 
distal nephron and no net acid retention occurs under steady-state conditions 3, 4. As a result, 
the classical promoters of calcium phosphate (CaP) stone formation encountered in type I 
dRTA and idRTA (hypercalciuria, hypocitraturia and alkalinuria) are not present in pRTA. Thus, 
with the exception of some specific rare scenarios (e.g. Fanconi syndrome associated with 
Dent’s disease), nephrocalcinosis and nephrolithiasis are not common features of pRTA. 
Hyperkalemic forms of RTA: low urinary pH and uric acid stones  
In contrast to pRTA, all forms of dRTA may be associated with recurrent kidney stones. The 
pathogenic mechanisms of stone formation are similar for hypokalemic type I, combined type 
III and incomplete dRTA, stone formation. In hyperkalemic forms of dRTA, however, the 
mechanism  is  different. Hyperkalemic dRTA associated with aldosterone deficiency, also 
known as Type IV RTA, is the most frequent form of RTA encountered clinically and is 
characterized by low urine pH and decreased acid excretion. This is in contrast to other forms 
of hyperkalemic dRTA where aldosterone is not decreased and urine pH always fails to 
decrease  as discussed elsewhere in this issue. Calcareous stone formation is uncommon in 
patients with hyperkalemic forms of dRTA 5-8. A main reason for that is that patients with 
hyperkalemic RTA have typically some degree of CKD with marked reduction in urinary 
calcium excretion. Type IV dRTA can potentially be a cause of uric acid calculi, especially if 
associated with low urine pH (<5.5), type II diabetes or high body mass index (BMI) 9-11. Note 
that the majority of classic uric acid stone formers (SF) have unduly aciduria but  rarely have 
hyperkalemic RTA 12. The fundamental pathophysiology in idiopathic uric acid nephrolithiasis 
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is an increased acid load to the kidney and inadequate ammonia production/excretion 13. The 
solubility of undissociated uric acid is low; ~0.5 mM in human urine at 37 °C. Thus, at a urine 
pH of 5.35 (pKa of uric acid), only ~1 mM uric acid (sum of dissociated and undissociated forms 
of uric acid) can be solubilized. Physiological concentrations of uric acid in the urine are 
typically > 1 mM, and as such uric acid stone formation is a simple consequence of a low 
urinary pH. Low urinary pH in type IV RTA is due to a shortage of the urinary buffer ammonium, 
caused by hyperkalemia-induced impaired ammoniagenesis in the proximal tubule 9, 11, 14. 
Treatment of uric acid calculi associated with hyperkalemic type IV RTA should be targeted at 
eliminating the underlying cause (e.g. cessation of offending drugs, treatment of obstructive 
uropathy). If this is not feasible, increase of urinary pH by alkali supplementation effectively 
prevents stone formation. 
Hypokalemic distal RTA (Type I): High urinary pH and calcium phosphate stones 
The first description of type I dRTA in an autopsy series with six children was presented by 
Lightwood in 1935 15. Albright and associates recognized the tubular origin of the entity in 1946 
and the term “renal tubular acidosis” was coined by Pines and Mudge in 1951 16, 17. Type I 
dRTA can be acquired or inherited (Table 2). A myriad of acquired causes are known to cause 
type I dRTA, the most classical one being Sjögren’s syndrome with autoantibodies directed at 
α–intercalated cells 18. For familial cases, autosomal-recessive and autosomal-dominant 
mutations in the anion exchanger 1 (AE1, encoded by SLC4A1 gene), autosomal-recessive 
mutations in the B1 and a4 subunits of the V-ATPase (encoded by ATP6V1B1 and ATP6V0A4 
genes, respectively) and recently autosomal-recessive mutations in the transcription factor 
Foxi1 (encoded by the FOXI1 gene) have been identified as the underlying monogenic causes 
19-22. Overall, type I dRTA is considered a rare cause of calcareous nephrolithiasis 23, 24. 
Mechanistically, rate- (or capacity-) limited distal tubular H+ secretion is the reason for reduced 
urinary net acid excretion and alkaline urinary pH 25. Unlike in pRTA, there is systemic H+ 
retention in patients with type I dRTA 3, 4. As a consequence of H+ retention, intestinal calcium 
absorption and release of calcium from bone increase and renal calcium reabsorption 
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decreases, resulting in hypercalciuria. 26-28. Hypocitraturia due to avid reclamation of citrate by 
proximal tubular cells in the setting of systemic acidosis is another hallmark of type I dRTA.  
The sequelae of type I dRTA are recurrent nephrolithiasis, nephrocalcinosis and bone disease. 
The three key prolithogenic factors in type I dRTA (hypercalciuria, hypocitraturia and relatively 
alkaline to very alkaline urinary pH) favor CaP precipitation (Fig. 1). The typical calculus in type 
I dRTA consists of carbonate apatite (95.7%) with only minute brushite admixture (1.4%) and 
has a characteristic morphology with a smooth aspect and a glazed brown-yellow appearance 
with tiny cracks 29, 30. Stone composition similar to dRTA is observed in patients with carbonic 
anhydrase inhibitor treatment (acetazolamide, topiramate). In contrast, patients with primary 
hyperparathyroidism and renal phosphate leak typically have CaP stones that contain 
significantly more brushite (29.1 and 23.9% respectively) 29. The degree of CaP admixture is 
accurately reflected by the magnitude of brushite supersaturation 31. As the stone composition 
ranges from CaOx to mixed CaOx-CaP, to CaP, the prevalence of a urinary acidification deficit 
increases from 5 to 40% 32, 33.  
The concurrent existence of type I dRTA  and nephrocalcinosis has been known since 1950’s 
and the order of causality is likely bidirectional 34; i.e. nephrocalcinosis can be the result of 
dRTA or vice versa. The pathogenesis of nephrocalcinosis in type I dRTA is not known but 
possibly involves the same lithogenic factors that also foster the development of stones. The 
increase in basolateral uptake of citrate by the proximal tubule from the peritubular capillaries 
can lower interstitial citrate concentration as the vasa recta traverse the deep medulla. Counter 
to this effect is the reduced pumping of H+ into the tubular lumen which will decrease 
basolateral bicarbonate exit from the collecting duct and decrease interstitial pH, hence 
reducing the risk of CaP precipitation. Interstitial ectopic calcifications may also be a variant of 
Randall’s plaques which occurs without acidification defects 35. In familial cases, the 
prevalence of nephrocalcinosis typically depends on the severity of the disease with late 
occurrence in autosomal-dominant AE1 mutations but early and severe in autosomal-
recessive AE1 and V-ATPase mutations.  
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Unlike pRTA, patients with type I dRTA typically present with low bone mass primarily due to 
reduced bone formation and turnover rates, and to some extent defective mineralization and 
reduced non-collagenous proteins 36-38. Overt osteomalacia is rare in dRTA 36, but dRTA from 
Sjögren’s syndrome can be associated with proximal tubule phosphate wasting and secondary 
osteomalacia 39.  
 
Incomplete dRTA 
The entity “incomplete dRTA“ (idRTA) was first described by Wrong and Davies in 1959 40. 
They reported three patients with bilateral nephrocalcinosis without systemic metabolic 
acidosis (defined by hypobicarbonatemia) that were unable to maximally acidify the urine by a 
one day ammonium chloride acid loading test (0.1g NH4Cl/Kg body weight). Trough urinary pH 
reached were 5.73, 5.91 and 6.5, respectively. Trough urinary pH of 10 healthy subjects tested 
in the same study ranged from 4.59 to 5.24. Only one of the three patients with idRTA 
described was hypercalciuric, no patient had kidney stones. This entity is not commonly 
diagnosed because the routine clinical test are all normal. Since this original publication, the 
one day ammonium chloride loading test was considered the gold standard for the diagnosis 
of idRTA. Typically, a pH < 5.3 has been accepted as threshold to rule out idRTA but there has 
never been a clear consensus on this threshold pH and various other definitions have been 
employed in the past 24, 41-46. Using non-uniform definitions and provocative test procedures, a 
wide range of prevalence of idRTA from 2 to 21 % have been reported in recurrent SF 24, 47, 48. 
Much higher prevalence rates of idRTA were reported in subgroup of patients with recurrent 
CaP stones, chronic pyelonephritis, nephrocalcinosis or medullary sponge kidney.  
Unfortunately, gastrointestinal side effects occur frequently during ammonium chloride loading. 
Thus, in the decades following the first description, several alternative tests that impose an 
acute acid load with better tolerability or safety profile were introduced (furosemide, 
furosemide/fludrocortisone, reduced dose 3 day ammonium chloride test, arginine-HCl or 
calcium chloride loading test), but rigorous comparative studies of test procedures were lacking 
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49, 50. A recent prospective study in an unselected cohort of 170 SF compared the performance 
of the frequently used furosemide/fludrocortisone test or of non-provocative parameters 
against the gold standard one day ammonium chloride loading test. The study showed that the 
two non-provocative parameters, second morning fasting urinary pH <5.3 and plasma K+ >3.8 
mM/l, or the furosemide/fludrocortisone test had excellent negative predictive but low positive 
predictive values for the diagnosis of idRTA 51. Thus, idRTA can be reliably excluded in SF by 
either the use of the two non-provocative parameters of second morning fasting urinary pH 
and plasma K+ or the furosemide/fludrocortisone test. If idRTA cannot be excluded by either 
approach, the diagnosis can be sought by the ammonium chloride loading test. The study also 
revealed that there was a negative association of nadir urinary pH in the ammonium chloride 
test with 24 h urinary citrate excretion, SF with idRTA had significantly lower urinary citrate 
than SF without idRTA. With respect to 24 h urinary calcium excretion, no differences were 
found between SF with or without idRTA. 
IdRTA shares many features of overt type I dRTA, including urinary traits (hypercalciuria, 
hypocitraturia and alkaline pH) and the association with nephrolithiasis and nephrocalcinosis. 
The degree of biochemical urinary abnormalities is typically less severe than in type I dRTA 
and especially hypercalciuria is often not seen in idRTA. An important but often neglected 
difference between type I dRTA and idRTA is the fact that ammonium excretion is typically 
normal or occasionally increased in idRTA while it is significantly reduced in the case of type I 
dRTA 44, 52. Thus, although no rigorous balance studies have been performed as in type I dRTA 
or pRTA, idRTA patients are classically considered to be in acid-base steady-state (i.e. stable 
serum bicarbonate concentration).  
Low bone mass is a frequent finding in recurrent SF, vertebral fracture risk is increased four-
fold compared to non-SF 53, 54. idRTA may also be associated with low bone mass, but it is not 
as established as in type I dRTA. Osther et al. first reported increased markers of bone 
formation and bone resorption in SF with idRTA compared to SF without idRTA 55. In patients 
with primary osteoporosis, Weger et al. discovered a high prevalence of idRTA 56, 57 and 
children with idRTA exhibit significantly reduced height 58. However, in a population-based 
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study in an area of endemic tubular acidosis, idRTA was not associated with lower bone mass 
59. Furthermore, a recent study in 150 recurrent SF found no difference in bone mineral density 
between patients with and without idRTA 60.  Thus, additional longitudinal studies are needed 
to examine if a urinary acidification defect in the absence of frank systemic acidosis is 
associated with reduced bone mass and/or increased fracture risk. 
IdRTA is typically considered an acquired condition (e.g. Sjögren’s syndrome, lithium therapy), 
but familial associations have been described (e.g. medullary sponge kidney). Rarely, idRTA 
may represent a “pre-acidotic” forme fruste version of type I dRTA, patients with transition of 
idRTA to overt type I dRTA have been described and causes of idRTA and type I dRTA overlap 
(e.g. nephrocalcinosis, Sjögren’s syndrome) 40, 52, 61. Unfortunately, longitudinal studies in 
patients with idRTA are lacking and we do not know which patients with idRTA will eventually 
progress to type I dRTA. Certainly, given the large prevalence difference of overt type I dRTA 
and idRTA in recurrent SF, transition from idRTA to type I dRTA must be a rare event. 
In most SF with idRTA, the cause of the urinary acidification deficit remains obscure. Since we 
do not usually obtain tissue, some form of unrecognized interstitial nephritis may be present in 
some patients. An important recent finding is that heterozygous carriers in a large family with 
an autosomal-recessive V-ATPase B1 subunit truncation mutation (p.F468fsX487) or SF 
heterozygous for the non-synonymous polymorphism p.E161K in the V-ATPase B1 subunit 
are not normal but exhibit a urinary acidification deficit, compatible with idRTA 62, 63. These 
findings are compatible with haploinsufficiency of B1 in humans. If other known V-ATPase B1 
or a4 subunit missense mutations also cause a detectable deficit in urinary acidification in a 
heterozygous state is currently unknown but is worthy of investigation. Thus, it is conceivable 
that allelic variants of genes involved in H+ secretion in α–intercalated cells or in ammonia 
synthesis in proximal tubular cells are associated with a urinary acidification deficit and thus 
the development of idRTA. It is noteworthy that the heterozygous carriers look 
indistinguishable from the regular idiopathic calcium SF and can be missed. The clinical 
features of the p.E161K heterozygotes include younger age of onset, more likely to have a 
positive family history, higher incidence of CaP stones, and an abnormally high trough urine 
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pH upon NH4Cl challenge 62, 63. 
Treatment of nephrolithiasis in type I dRTA and incomplete dRTA 
The management of dRTA needs to be directed at the treatment of the underlying cause if one 
can be identified and is amenable to therapy. Interstitial nephritis and dRTA of Sjögren‘s 
syndrome typically respond to immunosuppressive therapy 64. Alkali is the cornerstone of 
therapy if definitive elimination of the underlying causes is not possible. The situation is clear 
in children with congenital forms of type I dRTA with metabolic acidosis which leads to reduced 
GFR, treatment with alkali improves bone and somatic growth 65, 66. Sodium bicarbonate 
supplementation normalizes height in children with idRTA and preserved GFR 67. 
In adults, treatment indication and modality are less well established. There are no true RCTs 
for stones prevention in adults with type I dRTA or idRTA 48. Even RCTs for calcareous stones 
in the absence of dRTA have not addressed specifically the outcomes of patients with CaP 
stones. In small studies, treatment with alkali in adults with either dRTA or idRTA decreased 
skeletal Ca mobilization and hypercalciuria, increased bone density, increased citraturia and 
reduced stone formation 26, 38, 68, 69. K-citrate is preferable over Na-citrate because K-citrate 
tends to reduce calciuria in addition to increasing citraturia and improves CaOx saturation. In 
contrast, Na-citrate at equimolar doses can increase calciuria and saturation for brushite and 
Na-urate while leaving that of CaOx unchanged 68. In patients with dRTA associated with 
medullary sponge kidney which may represent a form of idRTA, alkali therapy also led to a 
decrease in stone passage and improvement of the associated bone disease 70-72. 
The amount of alkali needed to increase citraturia in SF with dRTA is hard to predict and even 
more challenging to adjust. Although compliance and gut absorption can be assured by 24 hr 
urine K excretion, it is not unusual that doses > 60 meq/d of potassium alkali are needed to 
significantly raise citraturia by only a few meq/d. The reason for the discrepancy between the 
kaliuresis and citraturia is not known. Apart from increasing citraturia, alkali therapy also raises 
urinary pH, potentially worsening brushite supersaturation and thus promote CaP stone 
formation. Unfortunately, due to the lack of RCT data we currently do not know at which point 
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benefit ends and harm starts with alkali therapy. Computer-based programs (Equil-2, JESS) 
can aid the clinician in estimating urinary brushite saturation and guide therapy 73-75. In contrast 
to saturation index (SI) calculated by JESS, relative supersaturation ratio (RSR) determined 
by Equil-2 seems to overestimate the pH effect on brushite saturation when compared to the 
empirically determined concentration-to-product ratio (CPR) (Figure 2) 73. Clinically it is 
important to consider both urinary pH and citrate when treating a patient with alkali. It is 
possible to raise urinary citrate by small amounts (e.g. 2 mmoles/d) which may not be 
accompanied with alkalinuria but adequate to chelate urinary calcium.  If the increase in urinary 
pH is not paralleled by a concomitant rise in urinary citrate, alkali therapy will be harmful. 
Alternatively, thiazide diuretics can be employed to reduce calciuria which will reduce urinary 
brushite saturation by decreasing urinary calcium and pH 76. 
Provocative thoughts on provocative diagnostic testing for incomplete dRTA  
Since the initial description of the unmasking procedure by provocative testing, idRTA was 
always considered a separate entity and patients suffering from it a distinct group of SF. 
Traditionally, only selected SF (e.g. alkaline fasting urinary pH, CaP-containing stones or 
unexplained hypocitraturia) were subjected to provocative testing in clinical practice. 
Prospective studies in which large cohorts of unselected SF underwent provocative testing are 
lacking. Recent data challenges the dogma of idRTA as a separate entity 51, 77. In an unselected 
cohort of 170 SF, urinary acidification capacity was found to be not a dichotomous but a 
continuous trait (Figure 3). Hypercalciuria, hypocitraturia and low bone mass are variable 
characteristics encountered in all calcareous SF and equally variable for idRTA.  
In addition to the classical read-out of urinary pH and acid excretion one can also prepare 
membranes from the urine that contains various fractions such as exosomes or ectosomes 
that can serves as a ‘window” permitting a glimpse at the apical membrane of the renal tubules 
in humans 78. While normal subjects showed an increase in the B1 subunits in urine pellets in 
response to an acid load, it is was not observed in patients with dRTA 79, 80. 
- 12 - 
 
As outlined above, there are no randomized clinical trials in SF with idRTA. In small studies, 
treatment with alkali in adult SF with idRTA decreased hypercalciuria, increased citraturia, 
reduced stone formation and improved associated bone disease 26, 68, 70-72, 81. Results of these 
uncontrolled studies suggested that SF with idRTA indeed constitute a unique subset of 
patients that may benefit from alkali treatment. However, alkali treatment was also found to be 
effective in the recurrence prevention in unselected cohorts of calcareous SF 82. Thus, 
longitudinal and interventional trials are needed to further explore the prognostic and 
therapeutic relevance of diagnosing idRTA in SF. Until the advent of such studies, provocative 
testing for idRTA diagnosis should ,in our opinion ,be prescribed only conservatively in clinical 
routine and be mainly viewed as a research tool. 
Combined proximal-distal RTA (Type III) 
Combined proximal-distal RTA (Type 3) is a rare entity which was originally described as a 
transient condition in children 83. The genetic condition with osteopetrosis and RTA is due to 
congenital type II carbonic anhydrase deficiency 84, 85. A more common form of combined p-
dRTA is from carbonic anhydrase inhibition. In a small study of 27 elderly patients receiving 
acetazolamide (250 to 1,000 mg/day) for glaucoma, 4 patients had mild acidosis (pH 7.29 - 
7.31), 10 had moderate acidosis (pH 7.20 - 7.29), and 1 severe acidosis (pH 7.15) 86. Another 
drug that has multiple properties with one being carbonic anhydrase inhibition is topiramate 
which is used to treat seizures, migraine headache, weight loss, and many other off-label use.  
The chemical lithogenicity is identical to that of dRTA composed of alkalinuria, hypocitraturia, 
and modest hypercalciuria giving rise to CaP stones. When normal individuals were given 
topiramate, all of them developed alkalinuria, hypocitraturia and double the relative saturation 
ratio of brushite 87. While biochemical stone risks are increased in every subject on topiramate, 
not all subjects gets kidney stones. The prevalence of kidney stones are dependent on dose 
and duration of therapy (Table 3). In some, though not all of the studies, imaging was used to 
detect asymptomatic stones. Once stones start forming, it is very unlikely that they will subside. 
The best countermeasure is a discussion with the neurologist to explore alternative therapy if 
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possible. If cessation is not possible and topiramte has to be continued, alkali in the form of 
potassium citrate can be administered 88. 
Conclusions 
RTA’s encompass a broad group of congenital or acquired disorders, characterized by 
defective renal acid excretion, which can lead to recurrent kidney stones and nephrocalcinosis. 
Hyperkalemic RTA can be occasionally associated with uric acid nephrolithiasis, in the setting 
of type II diabetes or the metabolic syndrome but it is not a main cause of uric acid stones. 
Proximal type II RTA is very rarely associated with urolithiasis or nephrocalcinosis. In contrast, 
CaP stones and nephrocalcinosis are frequently encountered in patients with hypokalemic type 
I dRTA or idRTA. While the former can be diagnosed by conventional clinical criteria, diagnosis 
of idRTA is classically only achieved with provocative acid loading tests. SF that cannot acidify 
urine pH <5.3 during provocative testing are considered to have idRTA. In addition to alkaline 
urinary pH, hypercalciuria and hypocitraturia are the two other prolithogenic urinary 
abnormalities encountered in SF with idRTA which are also encountered in SF without idRTA.  
Urinary acidification capacity is a continuous trait, questioning the view of idRTA as a separate 
entity. Alkaline urinary pH > 6 is an important lithogenic factor for CaP stone formation and can 
easily be detected by spot fasting or 24 h urine pH measurements. The value of idRTA 
diagnosis by provocative testing and genotyping the candidate genes, are important research 
tools but remains unclear at the moment whether they alter clinical practice, and need further 
clarification. Similarly, no randomized clinical trials have been performed in SF with dRTA or 
CaP stones. Until the availability of such data, one should focus treatment of SF with CaP 
stones on the biochemical abnormalities encountered in the metabolic work-up. SF with type I 
dRTA should receive alkali therapy, preferentially in the form of K-citrate delivered cautiously, 
to treat the chronic acid retention which drives both stone formation and bone disease. 
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Table 1. Classification of renal tubular acidosis by nephron segment and phenotypic features 
 
  Tubular 
segment 
Numeric 
type Synonym(s) Plasma chemistry Urine chemistry Clinical features 
Proximal II • Proximal  • NAG metabolic acidosis  
• Hypokalemia (when given 
alkali) 
• Hypophosphatemia (if 
part of Fanconi) 
Maximally acidic urine in the 
absence of bicarbonaturia. 
Alkalinuria when plasma 
[HCO3-] is raised to normal. 
b2-microglobulinuria in the 
absence of albuminuria. 
No nephrolithiasis 
Distal I • Hypokalemic 
distal 
• NAG metabolic acidosis  
•  Hypokalemia 




IV • Hyperkalemic 
distal 
• NAG metabolic acidosis  
• Hyperkalemia 
Urine pH <6 
Low urinary ammonium 
Increased risk of uric acid 
nephrolithiasis if urinary pH 












• NAG metabolic acidosis  
 






Table 2. Inherited  distal tubular acidosis 
 
Gene  Mode of inheritance Clinical features 
ATP6V1B1  Autosomal-recessive Early onset sensorineural hearing loss. 
ATP6V0A4  Autosomal-recessive Late onset sensorineural hearing loss. 
SLC4A1 Autosomal recessive or autosomal-dominant  Hemolytic anemia (rare). 
FOXI1 Autosomal-recessive Early onset sensorineural hearing loss. 
CAII Autosomal-recessive Mixed pRTA and dRTA 
Autoimmune 
diseases  
Sjögren syndrome. Systemic lupus erythematosus, 
Cryoglubulinemia. Primary biliary cirrhosis. Thyroiditis  
Dysproteinemic 
states  Hyperglobulinemia, Paraprotein states. 
Endocrine 
hypercalciuria  
Hyperparathyroidism. Vitamin D intoxication. Medullary sponge 
kidney. Idiopathic hypercalciuria 
Drugs and toxins  Amphotericin B. Lithium. Vanadate. Cyclamate. Carbonic anhydrase inhibitors (topiramate, acetazolamide) 
Tubulointerstitial 
disease  
Interstitial nephritis. Chronic pyelonephritis. Obstructive uropathy. 
Balkan nephropathy. Renal transplantation, bariatric surgery with 
hyperoxaluria 
























Incidence  References 
89-95 
? ? 250-450 mg ? 1.5 % Product monograph 
170 47 250-450 mg 6 1.8 % Stephen et al. Epilepsia 2000 
45 16 4 mg/Kg 15.8 4.5 % Coppola et al. Epilepsy Res 2002a 
18 9 5 mg/Kg 11.9 5.6 % Coppola et al. Epilepsy Res 2002b 
197 58 400-800 mg 12 9.1 % Cudkowicz et al. Neurology 2003 
24 21 7.9 mg/kg 34 54 % Goyal et al. Ped Neurology 2009 
96 7 5 mg/kg 12 5.2 % Mahmoud et al. Epilepsia 2011 
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Figure 1. The three key prolithogenic urinary abnormalities in type I dRTA. Urinary 
abnormalities are similar in type I dRTA and idRTA but typically less severe in the latter. In 
contrast do dRTA, hypercalciuria is not a common finding in idRTA. The proposed underlying 
mechanisms are shown. 
 
Figure 2. Brushite saturation in relation to urinary pH (A) und urinary citrate concentration (B). 
RSR (relative supersaturation ratio) and SI (saturation index) are calculated by the two 
programs EQUIL-2 (RSR) and JESS (SI). CPR (concentration-to-product ratio) is based on 
empirical physicochemical determination of brushite saturation in urine. Data are taken from 
Pak et al. 73, 96. 
 
Figure 3. Histogram of urinary pH nadir achieved in ammonium chloride test in unselected 
cohort of 168 SF with Kernel density plot. Data are taken from Dhayat et al. 51. 
 
 
 
 
 
 
 
 
  
